May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Selective Laser Trabeculoplasty as Initial and Adjunctive Treatment for Open–Angle Glaucoma
Author Affiliations & Notes
  • C. Hutnik
    Ophthalmology, Ivey Eye Institute, London, ON, Canada
  • I. McIlraith
    Ophthalmology, Ivey Eye Institute, London, ON, Canada
  • G. Colev
    Ophthalmology, Ivey Eye Institute, London, ON, Canada
  • M. Strasfeld
    Ophthalmology, Ivey Eye Institute, London, ON, Canada
  • Footnotes
    Commercial Relationships  C. Hutnik, None; I. McIlraith, None; G. Colev, None; M. Strasfeld, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 113. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Hutnik, I. McIlraith, G. Colev, M. Strasfeld; Selective Laser Trabeculoplasty as Initial and Adjunctive Treatment for Open–Angle Glaucoma . Invest. Ophthalmol. Vis. Sci. 2005;46(13):113.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : </ul> Purpose:To investigate the efficacy and safety of selective laser trabeculoplasty as an initial treatment for newly diagnosed open–angle glaucoma, as well as its role as adjunctive therapy. Methods: A prospective, multi–center non–randomized clinical trial was performed. Patients with newly diagnosed open–angle glaucoma and ocular hypertension were divided into the primary (selective laser trabeculoplasty) treatment group or the control (latanoprost) group according to patient choice. Both groups were followed at 1, 3, 6, and 12 months. A secondary treatment group was also included to study the efficacy of selective laser trabeculoplasty for patients intolerant of or failing medical therapy, with or without a history of previous argon laser trabeculoplasty. Results: One hundred eyes (61 patients) were enrolled, 74 in the primary treatment group, and 26 in the control group. The average absolute and percent reductions in intraocular pressure for the primary treatment group were 8.3 mmHg or 31.0%, compared to 7.7 mmHg or 30.6% for the control group (p=0.208 and p=0.879). The responder rates (20% pressure reduction) were 83% and 84% for the primary and control groups. There were no differences in intraocular pressure lowering with selective laser trabeculoplasty based on angle pigmentation. A modest contralateral effect was observed in the untreated fellow eyes of patients undergoing SLT therapy. Conclusions: SLT was found to be equally efficacious as latanoprost in reducing intraocular pressure in newly diagnosed open–angle glaucoma and ocular hypertension over 12 months, independent of angle pigmentation. Non–steroidal anti–inflammatory therapy post–laser had similar efficacy to steroids post laser. These findings support the consideration of selective laser trabeculoplasty as a first line treatment for newly diagnosed open angle glaucoma and ocular hypertension. Key Words: selective laser trabeculoplasty, open–angle glaucoma, treatment, intraocular pressure

Keywords: laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×